CN111556868B - 放射性核素标记化合物和含有该化合物的显影剂 - Google Patents

放射性核素标记化合物和含有该化合物的显影剂 Download PDF

Info

Publication number
CN111556868B
CN111556868B CN201980007415.2A CN201980007415A CN111556868B CN 111556868 B CN111556868 B CN 111556868B CN 201980007415 A CN201980007415 A CN 201980007415A CN 111556868 B CN111556868 B CN 111556868B
Authority
CN
China
Prior art keywords
radionuclide
labeled compound
salt
amyloid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980007415.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111556868A (zh
Inventor
季斌
樋口真人
须原哲也
陈忠正
藤本央介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fuji Medical Technology Co ltd
Original Assignee
Shanghai Fuji Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fuji Medical Technology Co ltd filed Critical Shanghai Fuji Medical Technology Co ltd
Publication of CN111556868A publication Critical patent/CN111556868A/zh
Application granted granted Critical
Publication of CN111556868B publication Critical patent/CN111556868B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980007415.2A 2018-01-12 2019-01-11 放射性核素标记化合物和含有该化合物的显影剂 Active CN111556868B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-003564 2018-01-12
JP2018003564A JP6831802B2 (ja) 2018-01-12 2018-01-12 放射性核種標識化合物及びこれを含有するイメージング剤
PCT/IB2019/000060 WO2019138296A2 (ja) 2018-01-12 2019-01-11 放射性核種標識化合物及びこれを含有するイメージング剤

Publications (2)

Publication Number Publication Date
CN111556868A CN111556868A (zh) 2020-08-18
CN111556868B true CN111556868B (zh) 2023-03-28

Family

ID=67218458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980007415.2A Active CN111556868B (zh) 2018-01-12 2019-01-11 放射性核素标记化合物和含有该化合物的显影剂

Country Status (5)

Country Link
JP (1) JP6831802B2 (enExample)
KR (1) KR102428569B1 (enExample)
CN (1) CN111556868B (enExample)
TW (1) TWI818946B (enExample)
WO (1) WO2019138296A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115989029B (zh) * 2020-08-25 2025-07-22 国立研究开发法人量子科学技术研究开发机构 化合物、α突触核蛋白凝集体结合剂及其利用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867552A (zh) * 2003-08-13 2006-11-22 株式会社Bf研究所 用于淀粉样蛋白积聚性疾病的探针、用于染色淀粉样蛋白的试剂、用于治疗或预防淀粉样蛋白积聚性疾病的药物、以及用于诊断神经原纤维缠结的探针以及用于染色神经原纤维缠结的试剂
WO2007063946A1 (ja) * 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
WO2008078424A1 (ja) * 2006-12-25 2008-07-03 Tohoku University ベンゾキサゾール誘導体
CN101466711A (zh) * 2006-05-19 2009-06-24 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CN103534253A (zh) * 2011-05-20 2014-01-22 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CN103596950A (zh) * 2011-06-24 2014-02-19 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CN104736524A (zh) * 2012-12-21 2015-06-24 独立行政法人放射线医学总合研究所 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物
CN105229009A (zh) * 2013-05-23 2016-01-06 豪夫迈·罗氏有限公司 作为成像剂的2-苯基咪唑并[1,2-a]嘧啶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381604B1 (en) * 2001-04-23 2006-12-27 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2005016888A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
JP4738443B2 (ja) * 2007-05-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患のイメージング薬及び治療薬
JP2011524864A (ja) * 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867552A (zh) * 2003-08-13 2006-11-22 株式会社Bf研究所 用于淀粉样蛋白积聚性疾病的探针、用于染色淀粉样蛋白的试剂、用于治疗或预防淀粉样蛋白积聚性疾病的药物、以及用于诊断神经原纤维缠结的探针以及用于染色神经原纤维缠结的试剂
WO2007063946A1 (ja) * 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
CN101466711A (zh) * 2006-05-19 2009-06-24 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
WO2008078424A1 (ja) * 2006-12-25 2008-07-03 Tohoku University ベンゾキサゾール誘導体
CN103534253A (zh) * 2011-05-20 2014-01-22 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CN103596950A (zh) * 2011-06-24 2014-02-19 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CN104736524A (zh) * 2012-12-21 2015-06-24 独立行政法人放射线医学总合研究所 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物
CN105229009A (zh) * 2013-05-23 2016-01-06 豪夫迈·罗氏有限公司 作为成像剂的2-苯基咪唑并[1,2-a]嘧啶

Also Published As

Publication number Publication date
TW201929909A (zh) 2019-08-01
CN111556868A (zh) 2020-08-18
JP6831802B2 (ja) 2021-02-17
KR102428569B1 (ko) 2022-08-03
TWI818946B (zh) 2023-10-21
JP2019123675A (ja) 2019-07-25
WO2019138296A2 (ja) 2019-07-18
WO2019138296A3 (ja) 2019-10-03
KR20200109335A (ko) 2020-09-22

Similar Documents

Publication Publication Date Title
Ono et al. Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer’s disease
Ono et al. Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains
Ono et al. Development of novel β-amyloid probes based on 3, 5-diphenyl-1, 2, 4-oxadiazole
KR102530129B1 (ko) 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도
CN103534253B (zh) 对淀粉状蛋白具有亲和性的化合物
Matsumura et al. Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer’s disease
JPWO2009057578A1 (ja) 新規アミロイド親和性化合物の使用及び製造方法
Wang et al. 99mTc-labeled-2-arylbenzoxazole derivatives as potential Aβ imaging probes for single-photon emission computed tomography
CN111556868B (zh) 放射性核素标记化合物和含有该化合物的显影剂
Ono et al. Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease
JP5954737B2 (ja) 放射性フッ素標識キノキサリン化合物
Watanabe et al. Synthesis and biological evaluation of radioiodinated 2, 5-diphenyl-1, 3, 4-oxadiazoles for detecting β-amyloid plaques in the brain
JP6260967B2 (ja) 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
JP2013237655A (ja) コンフォメーション病診断用分子プローブ
WO2012176587A1 (ja) 新規アミロイド親和性化合物
CN108290883B (zh) 用于tau成像的氮杂环丁烷衍生物
JP6609868B2 (ja) 放射性ハロゲン標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物
HK40030316B (en) Radionuclide-labeled compound and imaging agent containing same
HK40030316A (en) Radionuclide-labeled compound and imaging agent containing same
WO2014132919A1 (ja) 診断用組成物
WO2020032038A1 (ja) モノアミンオキシダーゼｂイメージングプローブ
HK1240579A1 (en) Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound
CN107207499A (zh) 经放射性碘标记的吡啶并[1,2‑a]苯并咪唑衍生物化合物
HK1257042B (en) Azetidine derivatives for tau imaging
WO2011110488A1 (en) A novel pet imaging agent of amyloid plaques and its precursor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40030316

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220316

Address after: 200333 room 4025, floor 4, No. 1 Lane 879, Zhongjiang Road, Putuo District, Shanghai

Applicant after: Shanghai Fuji Medical Technology Co.,Ltd.

Address before: 200233 3rd floor, building 12, 470 Guiping Road, Xuhui District, Shanghai

Applicant before: SHANGHAI CHARTWELL MEDICAL INSTRUMENT Co.,Ltd.

GR01 Patent grant
GR01 Patent grant